Netherlands· NL-0c5a7fb98360
Yeytuo 464 mg oplossing voor injectie
A lenacapavir product containing lenacapavir natrium, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Lenacapavir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX31 (lenacapavir), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Lenacapavir · ATC J05AX31
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lenacapavir costs, country by country.
Normalised to the WHO defined daily dose (0.19 g), the median price runs from $0.45 in France to $511.10 in Switzerland — a ×1140 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lenacapavir · price per daily dose (0.19 g)
USD · FX 28 Sept 2026
- CH Switzerland$511.10
- FR France$0.45
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LENACAPAVIR NATRIUM
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Netherlands (NL)
- ATC code
- J05AX31
- ATC class
- Lenacapavir
- Defined daily dose
- 0.19 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/25/1976
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lenacapavir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceSUNLENCA 464 mg, solution injectableGILEAD SCIENCES IRELAND UC (IRLANDE)
- IrelandYeytuo 464 mg solution for injectionGilead Sciences Ireland Unlimited Company
- United StatesSunlencaGilead Sciences, Inc.
- BelgiumSunlenca 300 mgGilead Sciences Ireland UC
- CzechiaSUNLENCAGilead Sciences Ireland UC, Carrigtohill
- FinlandSunlencaGilead Sciences Ireland UC
- IcelandSunlencaGilead Sciences Ireland UC*
- PolandSunlencaGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sunlenca, Yeytuo
- Liechtenstein · Sunlenca, Yeytuo
- Norway · Sunlenca, Yeytuo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c88c2a62-0c74-43c7-8a0e-81e15d1feead GET /v1/drugs/c88c2a62-0c74-43c7-8a0e-81e15d1feead?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/yeytuo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Lenacapavir",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134812",
"excipients": [
"MACROGOL 300",
"WATER VOOR INJECTIE"
],
"substances": [
"LENACAPAVIR NATRIUM"
],
"leaflet_url": null,
"authorised_at": "2025/08/25",
"procedure_number": "EMEA/H/C/006658",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/25/1976",
"additional_monitoring": "N"
}See everything about lenacapavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.